JP5552048B2 - 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド - Google Patents

加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド Download PDF

Info

Publication number
JP5552048B2
JP5552048B2 JP2010513493A JP2010513493A JP5552048B2 JP 5552048 B2 JP5552048 B2 JP 5552048B2 JP 2010513493 A JP2010513493 A JP 2010513493A JP 2010513493 A JP2010513493 A JP 2010513493A JP 5552048 B2 JP5552048 B2 JP 5552048B2
Authority
JP
Japan
Prior art keywords
seq
connexin
amino acid
disclosed
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010513493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530903A (ja
JP2010530903A5 (enExample
Inventor
ローラー，バーベル
ゴーディエ，ロバート
Original Assignee
ムスク ファンデーション フォー リサーチ ディベロップメント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ムスク ファンデーション フォー リサーチ ディベロップメント filed Critical ムスク ファンデーション フォー リサーチ ディベロップメント
Publication of JP2010530903A publication Critical patent/JP2010530903A/ja
Publication of JP2010530903A5 publication Critical patent/JP2010530903A5/ja
Application granted granted Critical
Publication of JP5552048B2 publication Critical patent/JP5552048B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010513493A 2007-06-21 2008-06-23 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド Expired - Fee Related JP5552048B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94549307P 2007-06-21 2007-06-21
US60/945,493 2007-06-21
PCT/US2008/067944 WO2008157840A2 (en) 2007-06-21 2008-06-23 Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2010530903A JP2010530903A (ja) 2010-09-16
JP2010530903A5 JP2010530903A5 (enExample) 2011-08-04
JP5552048B2 true JP5552048B2 (ja) 2014-07-16

Family

ID=40156983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513493A Expired - Fee Related JP5552048B2 (ja) 2007-06-21 2008-06-23 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド

Country Status (5)

Country Link
US (2) US20110130345A1 (enExample)
EP (1) EP2166845B1 (enExample)
JP (1) JP5552048B2 (enExample)
DK (1) DK2166845T3 (enExample)
WO (1) WO2008157840A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2438696C2 (ru) 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
JP2015515282A (ja) 2012-04-25 2015-05-28 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 創傷治癒および組織修復のための組成物および方法
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
EP3107939B1 (en) 2014-02-19 2020-06-17 University of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
ES2911714T3 (es) 2014-03-11 2022-05-20 Univ Florida Proteína M013 expresada por AAV como un terapéutico antiinflamatorio para su uso en un método de tratamiento de enfermedad ocular inflamatoria
JP7185655B2 (ja) * 2014-08-22 2022-12-07 オークランド ユニサービシーズ リミティド チャネル調節剤
CA2958879A1 (en) * 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
ES2804039A1 (es) * 2019-07-30 2021-02-02 Fund Profesor Novoa Santos Fragmentos peptidicos de cx43 para su uso como agentes senoliticos
MX2023004631A (es) * 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
CN119630693A (zh) * 2022-05-13 2025-03-14 凯瑞特生物科学公司 用于治疗年龄相关性黄斑变性的治疗用脂质加工组合物和方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US5234809A (en) * 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
PT2314321E (pt) * 1999-01-27 2014-09-26 Coda Therapeutics Inc Elemento de encaminhamento de um fluido de refrigeração de uma ferramenta de corte e processo para este encaminhamento
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
WO2002088370A2 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Autogene nucleic acids encoding a secretable rna polymerase
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6685971B2 (en) * 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
CN1827766B (zh) * 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
JP2003238441A (ja) * 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) * 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
US7560430B2 (en) * 2003-02-14 2009-07-14 Human Matrix Sciences, Llc Elastin digest compositions and methods utilizing same
EP2314689A3 (en) * 2003-12-03 2012-12-19 Coda Therapeutics (NZ) Ltd Antisense compounds targeted to connexins and methods of use thereof
RU2438696C2 (ru) * 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
CN101573131B (zh) * 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用

Also Published As

Publication number Publication date
US20140018305A1 (en) 2014-01-16
EP2166845A4 (en) 2012-08-01
EP2166845B1 (en) 2015-10-21
WO2008157840A2 (en) 2008-12-24
DK2166845T3 (en) 2016-02-01
WO2008157840A3 (en) 2009-02-12
US20110130345A1 (en) 2011-06-02
JP2010530903A (ja) 2010-09-16
EP2166845A2 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
JP5552048B2 (ja) 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
US10398140B2 (en) Alpha connexin C-terminal (ACT) peptides and methods of use thereof
JP5602891B2 (ja) 創傷治癒および組織再生を促進するための組成物および方法
US10092624B2 (en) Methods of treating cancers with peptide-based modulators
EP3582754B1 (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
CN101151043B (zh) 促进伤口愈合和组织再生的组合物和方法
CA2592285C (en) Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides
AU2012202117B2 (en) Compositions and methods for promoting wound healing and tissue regeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140523

R150 Certificate of patent or registration of utility model

Ref document number: 5552048

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees